PLUS-1

May 13, 2016May 13, 2016

Sophiris Presents Positive Data from Phase 3 Study of LUTS Drug Treatment at AUA 2016

News

Sophiris Bio, Inc., presented positive data from its ongoing Phase 3 clinical trial of topsalysin — assessing the drug candidate as a potential treatment for symptoms of benign prostatic hyperplasia (BPH) — as a ... Read more

November 13, 2015November 16, 2015

Sophiris’ BPH Phase 3 Study Reports Significant and Positive Results

News

Sophiris Bio, Inc., recently announced that patients with lower urinary tract symptoms of benign prostatic hyperplasia (BPH) who were being treated with its drug candidate, PRX302 (topsalysin), showed a “statistically significant” improvement after ... Read more